Sagimet Biosciences Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the quarter ended March 31, 2024, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as those terms are defined in Item 408 of Regulation S-K), except as follows:
On February 27, 2024, George Kemble, Ph.D., our Executive Chairman, adopted a Rule 10b5-1 trading arrangement providing for the sale of up to 299,308 shares of our Series A common stock, subject to certain conditions. The arrangement's expiration date is December 15, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.